Therapeutic efficacy of recombinant tumor necrosis factor α in an experimental model of human prostatic carcinoma

Edward R. Sherwood*, Theodore R. Ford, Chung Lee, James M. Kozlowski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Prostatic carcinoma represents the second leading cause of cancer mortality in men and is responsible for over 25,000 deaths each year. Currently, no curative therapy is available for metastatic carcinoma of the prostate. The present studies were undertaken to assess the efficacy of recombinant tumor necrosis factor α (TNF) in the therapy of experimental prostatic carcinoma. TNF was cytotoxic to the prostate cancer cell lines PC3, DU145, and LNCAP but not benign prostatic epithelial and stromal cells in vitro. The sensitivity of the prostatic carcinoma lines to TNF-mediated cytotoxicity was enhanced by the presence of actinomycin D. Intravenous administration of TNF (50-100 μg/kg) to nude mice bearing subcutaneous PC3 tumors resulted in significant inhibition of primary tumor growth compared to control. TNF was also effective in reducing the growth of intraabdominal PC3 tumors induced by intrasplenic injection of PC3. Furthermore, the incidence of microscopic PC3 foci in the spleen, liver, lung, and diaphragm was diminished in mice receiving TNF therapy. These studies demonstrate the potential of TNF in the therapy of human prostatic carcinoma.

Original languageEnglish (US)
Pages (from-to)44-52
Number of pages9
JournalJournal of Biological Response Modifiers
Volume9
Issue number1
StatePublished - Feb 1990

Keywords

  • Mice
  • Prostatic cancer
  • Recombinant tumor necrosis factor α

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Therapeutic efficacy of recombinant tumor necrosis factor α in an experimental model of human prostatic carcinoma'. Together they form a unique fingerprint.

Cite this